Related Experiment Video
Updated: Jul 18, 2026
07:32
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
Biomarkers in osteoarthritis
Steven Abramson1, Svetlana Krasnokutsky
1NYU Hospital for Joint Diseases, 301 East 17th Street, New York, New York 10003, USA.
Bulletin of the NYU Hospital for Joint Diseases
|November 24, 2006
Summary
Developing new osteoarthritis treatments (DMOADs) requires better imaging and biomarkers. These tools will help identify at-risk patients and predict responses to drugs, advancing osteoarthritis research.
Area of Science:
- Rheumatology
- Biomarker Discovery
- Osteoarthritis Pathophysiology
Background:
- Osteoarthritis (OA) is a progressive, disabling joint disease driven by an imbalance in tissue repair and degradation, involving cartilage, bone, and synovium.
- Current challenges in developing disease-modifying osteoarthritis drugs (DMOADs) include variable disease progression and limitations of standard radiography in assessing treatment efficacy.
- Radiographic progression does not always correlate with improvements in patient pain and function, highlighting the need for better outcome measures.
Purpose of the Study:
- To emphasize the critical need for advanced imaging techniques and validated chemical biomarkers in osteoarthritis research.
- To facilitate the development of effective disease-modifying osteoarthritis drugs (DMOADs).
- To identify patient subgroups at higher risk for OA progression and predict their response to novel therapeutic agents.
Main Methods:
- Review of current challenges in osteoarthritis drug development.
- Discussion of the role of advanced imaging in assessing OA progression.
- Exploration of the potential of chemical biomarkers for patient stratification and treatment response prediction.
Main Results:
- Advances in imaging and the validation of chemical biomarkers are essential for facilitating DMOAD development.
- Biomarkers can identify patients predisposed to disease progression.
- Biomarkers are crucial for predicting patient responses to structure-modifying OA drugs.
Conclusions:
- Improved imaging and validated biomarkers are key to overcoming current hurdles in osteoarthritis drug discovery.
- Biomarker discovery is crucial for personalized medicine approaches in OA treatment.
- Future research should focus on validating biomarkers and integrating advanced imaging into clinical trials for OA.
